Recurrence of ROP after Anti-VEGF Therapy: How Many, Which Ones, When, What, Where
|
|
- Chad Day
- 5 years ago
- Views:
Transcription
1 Recurrence of ROP after Anti-VEGF Therapy: How Many, Which Ones, When, What, Where Helen Mintz-Hittner, M.D. Department of Ophthalmology and Visual Science University of Texas-Health Science Center-Houston McGovern Medical School AAPOS-2016-Vancouver April 8th, 2016 I have no relevant financial relationships to disclose nor conflicts of interest to resolve. Helen Mintz Hittner, MD 1
2 Screening and Treatment with Anti-VEGF Screening: initial and follow-up: according to usual guidelines for active ROP. Treatment: at ETROP Type 1 (appropriate if Classical Stages or APROP is present): NOT BEFORE VEGF levels must be definitely increased must allow normal vascularization. NOT AFTER VEGF levels will eventually decrease contraction of substantial membrane formation will cause retinal detachment. Normal Inner Retinal Vascularization is Related to Gestational Age Precursors of inner retinal vessels arise from the optic disc at 14 weeks GA and reach the temporal ora serrata at 27 weeks GA. Anticipate avascular retina to be from 3 to 5 DD if <27 weeks GA. Laser of the undifferentiated peripheral avascular retina is unnecessary even if avascular retina is more than 2 DD (normal for term infants) increased DD of avascular retina is related to decreased GA. Helen Mintz Hittner, MD 2
3 20 wk 25 wk 30 wk 35 wk 40 wk Best Outcomes with Bevacizumab Monotherapy: 1. Larger visual fields because no peripheral retinal destruction; 2. Less myopia because AC growth factors not destroyed in peripheral retina. Worst Outcomes with Bevacizumab Monotherapy: Recurrence: **** Helen Mintz Hittner, MD 3
4 Factors Related to Recurrence Drug Selection Larger molecules will stay longer in the eye and in the blood (? in vulnerable tissues) with decreased # of recurrences. Smaller molecules may not stay long enough to allow completion of retinal vascularization) with increased # of recurrences. Factors Related to Recurrence Dose selection Higher dose may be associated with longer time before recurrences occur with decreased # of recurrences. Lower dose may be associated with shorter time before recurrences occur with increased # of recurrences. Helen Mintz Hittner, MD 4
5 Observations Regarding Recurrence Intravitreal bevacizumab monotherapy, especially in zone I, is beneficial; however, recurrences can cause adverse outcomes: How Many: Incidence is 8% infants; 7% eyes. Which Ones: Risk Factors are: 1) APROP; 2) Increased duration of hospital stay (cumulative adverse events); 3) Decreased birth weight When: Risk Period is from 45 to 55 wks AA ( 94%). Helen Mintz Hittner, MD 5
6 What: Characteristics of Recurrence: 1. Plus disease returns and does not go away (not similar to after the first treatment) 2. Intravitreal Neovascularization returns but will go away (similar to after the first treatment) Where: 2 sites: 1. Advancing Edge 2. Former Ridge and EFP Complex Rate of Growth of Advancing Edge is Important Recurrence: Advancing edge grows at a rate of 0.11 DD/wk [usually resulting in a retinal vascularization length of 1.76 DD beyond its location at the time of 1 st injection ]. No Recurrence: Advancing edge grows at a rate of 0.23 DD/wk [usually resulting in retinal vascularization length of 4.48 DD beyond its location at the time of 1 st injection]. Helen Mintz Hittner, MD 6
7 Stage 3+: At time of 2 nd Injection: At 2 Locations: Both the Advancing Edge And the Former Ridge and EFP Complex (Distance traveled from 1 st Rx to 2 nd Rx DD/wk) Initial Treatment: 35.1 wk AA (470 gm BW; 24 wk GA) Recurrence FA: 52.7 wk AA APROP: At time of 2 nd Injection: At 1 Location: Only the Advancing Edge (Distance traveled from 1 st Rx to 2 nd Rx DD/wk) Initial Treatment: 34.0 wk AA (450 gm BW; 23 wk GA) Recurrence FA: 48.9 wk AA Helen Mintz Hittner, MD 7
8 Stage 3+: 1 Injection (Distance traveled from 1 st Rx to 2 nd Rx DD/wk) Initial Treatment: 35.6 wk AA (495 gm BW; 23 wk GA) Final Appearance: 79.6 wk AA XX XX APROP: 1 Injection (Distance traveled from 1 st Rx to 2 nd Rx DD/wk) Initial Treatment: 32.9 wk AA (470 gm BW; 23 wk GA) Final Appearance: 83.3 wk AA XX XX Helen Mintz Hittner, MD 8
Retinopathy of Prematurity. Objectives. Normal Retina Development. ROP Pathogenesis 6/8/2018. Thomas W. Hejkal, MD, PhD Eye Consultants, PC
Retinopathy of Prematurity Thomas W. Hejkal, MD, PhD Eye Consultants, PC Chair Emeritus Department of Ophthalmology UNMC drhejkal@eyeconsultantspc.com (No commercial interests) Objectives Identify risk
More informationPros and Cons in the use of AntiVEGF therapy in ROP
MEDICAL SCHOOL FEDERAL UNIVERSITY OF RIO GRANDE DO SUL PORTO ALEGRE BRAZIL Pros and Cons in the use of AntiVEGF therapy in ROP João Borges Fortes Filho MD, PhD Professor of Ophthalmology DESPITE THE GREATER
More informationGrand Rounds. Jenny Temnogorod SUNY Downstate Medical Center Department of Ophthalmology September 19, 2013
Grand Rounds Jenny Temnogorod SUNY Downstate Medical Center Department of Ophthalmology September 19, 2013 History and Examination HPI: 2 day old SGA (small for gestational age, 37 weeks, BWt. 1760g) with
More informationEarly Human Development
Early Human Development 88 (2012) 937 941 Contents lists available at SciVerse ScienceDirect Early Human Development journal homepage: www.elsevier.com/locate/earlhumdev Treatment of retinopathy of prematurity
More informationLaser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity. Ilya Leskov, MD, PhD Shizuo Mukai, MD
Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity Ilya Leskov, MD, PhD Shizuo Mukai, MD Introduction Retinopathy of prematurity (ROP) is characterized by abnormal retinal
More informationROP. Therapies. Current. Randomizing infants to receive either retinal laser or intravitreal. How Laser and Anti-VEGF Compare
Current ROP How Laser and Anti-VEGF Compare Therapies With the publication of the BEAT-ROP study results in 2011, some clinicians were inclined to jump on the bevacizumab bandwagon, while others held back,
More informationPMA Weight (g) Diagnosis at IVB. at IVB
1 Klinik Mata Nusantara, Jakarta, Indonesia 2 Department of Ophthalmology, Princess Margaret Hospital for Children, University of Western Australia, Perth, Australia 3 Department of Ophthalmology, Sakai
More informationClinical Study Macular Development in Aggressive Posterior Retinopathy of Prematurity
BioMed Research International Volume 2015, Article ID 808639, 5 pages http://dx.doi.org/10.1155/2015/808639 Clinical Study Macular Development in Aggressive Posterior Retinopathy of Prematurity Hemang
More informationDiode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment
Diode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment Simona-Delia Nicoara; Cristina Cristian, MD; Iulian Irimescu, MD; Anne-Claudia Stefanut, MD, PhD; Gabriela
More informationRetinopathy of prematurity (ROP) is a disorder of retinal
INVITED COMMENTARY Retinopathy of Prematurity Alice L. Bashinsky Retinopathy of prematurity (ROP) is a vasoproliferative retinal disorder unique to premature infants. As premature births increase in many
More informationROP and Imaging. Deborah M Costakos MD, MS August 12, 2016
ROP and Imaging Deborah M Costakos MD, MS August 12, 2016 Acknowledgements Adam Dubis, Ph.D. Joseph Carroll, Ph.D. Ryan Vogel, MD Clinton Warren, MD C Devika Subramaniam, M.D. Fouad Zakla, M.D. Alana Trotter,
More informationA bs tr ac t. n engl j med 364;7 nejm.org february 17,
The new england journal of medicine established in 1812 february 17, 2011 vol. 364 no. 7 Efficacy of for Stage 3+ Retinopathy of Prematurity Helen A. Mintz-Hittner, M.D., Kathleen A. Kennedy, M.D., M.P.H.,
More informationClinical Study Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity
Ophthalmology, Article ID 257286, 5 pages http://dx.doi.org/10.1155/2014/257286 Clinical Study Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior
More information3/6/2014. None relevant to this talk. Michael Trese Associated Retinal Consultants Royal Oak, Michigan USA
None relevant to this talk Michael Trese Associated Retinal Consultants Royal Oak, Michigan USA Chicago March 2014 Whenever a drug is used with a Different dose than in the label larger or smaller Different
More informationINFANTS WITH birth weights less
CLINICAL SCIENCES of Retinopathy of Prematurity Michael X. Repka, MD; Earl A. Palmer, MD; Betty Tung, MS; for the Cryotherapy for Retinopathy of Prematurity Cooperative Group Objective: To report the timing
More informationAntivascular endothelial growth factor for retinopathy of prematurity Helen A. Mintz-Hittner a and Leah M. Best b
Antivascular endothelial growth factor for retinopathy of prematurity Helen A. Mintz-Hittner a and Leah M. Best b a Department of Ophthalmology and Visual Science, University of Texas Health Science Center,
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab
More informationBevacizumab and ROP: Review of an RCT. M Chakraborty UHW
Bevacizumab and ROP: Review of an RCT M Chakraborty UHW Sections ROP VEGF and its involvement in the pathogenesis of ROP Details of the study (BEAT-ROP) Methods Results Conclusions Limitations/controversies
More informationDr. Derek P. Brazil Centre for Vision and Vascular Science Queen s University Belfast
Vascular Stem Cells as a novel potential treatment for Retinopathy of Prematurity Dr. Derek P. Brazil Centre for Vision and Vascular Science Queen s University Belfast Centre for Vision and Vascular Science
More informationIntraoperative Visualization of Peripheral Retina with Wide-Angle Viewing Systems
Intraoperative Visualization of Peripheral Retina with Wide-Angle Viewing Systems Homayoun Tabandeh, M.D., MS, Francesco Boscia, M.D. 1. Retina -Vitreous Associates Medical Group, Los Angeles, California,
More informationOverview. Retinal vascularisation during development. Classification of ROP. Visual loss from retinopathy of prematurity: first global estimates
Visual loss from retinopathy of prematurity: first global estimates Overview ROP - the condition, risk factors and control ROP as a cause of visual loss Earlier estimates New global estimates MARCH seminar,
More informationTop Pediatric Retinal Diseases you don t want to miss! Retinopathy of Prematurity (ROP) Aggressive, Posterior ROP (AP ROP)
Top 10 10 Pediatric Retinal Diseases you don t want to miss! Polly Quiram MD, PhD Vitreoretinal Surgery, PA Retinal Update Jan 26th, 2018 ROP Retinoblastoma Coats disease Persistent fetal vasculature Familial
More informationOUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I
OUTCOMES AFTER LASER VERSUS COMBINED LASER AND BEVACIZUMAB TREATMENT FOR TYPE 1 RETINOPATHY OF PREMATURITY IN ZONE I JE MOON YOON, MD,* DONG HOON SHIN, MD,* SANG JIN KIM, MD, PHD,* DON-IL HAM, MD, PHD,*
More informationStudy of Incidence, Clinical Staging and Risk Factors of Retinopathy of Prematurity in Rural Area
Original Article Study of Incidence, Clinical Staging and Risk Factors of Retinopathy of Prematurity in Rural Area Neeraj Gupta, Narendra P Datti, *Beeregowda Y, Kanthamani Krishnappa, Krishnamurthy D
More informationCurrently, laser photocoagulation of the avascular
Volume 20 Number 6 / December 2016 Abri Aghdam et al 539 7. Beer PM, Wong SJ, Hammad AM, Falk NS, O Malley MR, Khan S. Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor
More informationChildhood blindness due to ROP
Childhood blindness due to ROP Number of blind children/10 million pop, by cause and level of development Proportion of blindness due to ROP, by World Bank region Estimates of numbers blind from ROP, by
More informationRetinopathy of Prematurity (ROP)
37 Retinopathy of Prematurity (ROP) Retinopathy of prematurity (ROP) is a vaso-proliferative disorder of the retina among preterm infants.neonates born at less than 32 weeks of gestation are at risk of
More informationClassification of ROP
Classification of ROP Thomas Lee 2 Keywords Retinopathy of prematurity (ROP) Threshold ROP Plus disease Neovascularization Avascular retina Retinopathy of prematurity (ROP) is an iatrogenic disease. Prior
More informationClinical Study Incidence of Retinopathy of Prematurity in Extremely Premature Infants
ISRN Pediatrics, Article ID 134347, 4 pages http://dx.doi.org/10.1155/2014/134347 Clinical Study Incidence of Retinopathy of Prematurity in Extremely Premature Infants Alparslan Fahin, Muhammed Fahin,
More informationRetinopathy of Pre maturity and Pediatric Services
Retinopathy of Pre maturity and Pediatric Services An appeal for a new project vehicle Vittala International Institute of Ophthalmology (An unit of the Sri Keshava Trust) CA Site 1, 2 Cross, 2 Main, Seventh
More informationScreening Examination of Premature Infants for Retinopathy of Prematurity
POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Screening Examination of Premature Infants for Retinopathy of Prematurity
More informationPCMCH ROP Screening Guidelines
PCMCH ROP Screening Guidelines An expert panel convened by PCMCH (the ROP Work Group) recommends the Canadian Paediatric Society s 2010 guidelines be adopted as Ontario s screening guidelines for ROP.
More informationA spectral-domain OCT study of formerly premature children. Prat Itharat MD May 30, 2008 Vanderbilt Eye Institute Preceptor: Dr.
A spectral-domain OCT study of formerly premature children. Prat Itharat MD May 30, 2008 Vanderbilt Eye Institute Preceptor: Dr. Recchia Background: Optical coherence tomography (OCT) OCT analogous to
More informationRetinopathy of Prematurity: A Visually Impairing Disorder Name English 12 Section 35 Professor Marchbanks September 29, 2005
Retinopathy of Prematurity: A Visually Impairing Disorder Name English 12 Section 35 Professor Marchbanks September 29, 2005 1 Retinopathy of prematurity (ROP) is a visually impairing disorder which occurs
More informationJiao Lyu 1, Qi Zhang 1, Chunli Chen 2,YuXu 1, Xunda Ji 1 and Peiquan Zhao 1*
Lyu et al. BMC Ophthalmology (2019) 19:60 https://doi.org/10.1186/s12886-019-1067-4 RESEARCH ARTICLE Open Access Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity
More informationOFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY
OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY GEETA A. LALWANI, MD, AUDINA M. BERROCAL, MD, TIMOTHY G. MURRAY, MD, MBA, MARIA
More informationProliferative diabetic retinopathy
Brit. J. Ophthal. (1970) 54, 535 Proliferative diabetic retinopathy Regression of optic disc neovascularization after retinal photocoagulation ENID TAYLOR Ophthalmic Department, St. Bartholomew's Hospital,
More informationRetinopathy of Prematurity (ROP)
Retinopathy of Prematurity (ROP) Retinopathy of prematurity (ROP) is a vaso- proliferative disorder of the retina among preterm infants. Neonates born at less than 32 weeks of gestation are at risk of
More informationVitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
https://doi.org/10.1186/s40942-018-0113-3 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity:
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationDordi Austeng, Department of Neuroscience, Box 593, Uppsala University, SE Uppsala, Sweden
Dissertation presented at Uppsala University to be publicly examined in Enghoffsalen, Ingång 50, Akademiska Sjukhuset, Uppsala, Saturday, June 12, 2010 at 09:15 for the degree of Doctor of Philosophy (Faculty
More informationA LONGITUDINAL DESCRIPTIVE STUDY ON RETINOPATHY OF PREMATURITY IN A TERTIARY CARE CENTRE IN SOUTH INDIA
A LONGITUDINAL DESCRIPTIVE STUDY ON RETINOPATHY OF PREMATURITY IN A TERTIARY CARE CENTRE IN SOUTH INDIA Mary Thomas 1, Sri Gautham Bodduluri 2, Krishnaja Mandava 3, M. Muthayya 4, Binu Ninan 5 1Associate
More informationComparison of Ocular and Developmental Outcomes in Laser-and Bevacizumab-treated Infants with Retinopathy of Prematurity
Ophthalmology Research: An International Journal 3(1): 13-22, 2015, Article no.or.2015.003 ISSN: 2321 7227 SCIENCEDOMAIN international www.sciencedomain.org Comparison of Ocular and Developmental Outcomes
More informationRETINOPATHY OF PREMATURITY (ROP) IS A RETINAL
Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error Results BJÖRN C. HARDER, FRANK C. SCHLICHTENBREDE, STEFAN VON BALTZ, WALDEMAR JENDRITZA, BETTINA JENDRITZA, AND JOST B. JONAS PURPOSE:
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationOphthalmology. Ophthalmology Services
Ophthalmology Ophthalmology Services The Ophthalmology service offers the latest and most comprehensive eye care for patients. With a dedicated team of eye surgeons and consultants, we treat vision problems
More informationPosterior Segment Update
Posterior Segment Update Featured Speaker: Dr. Kyle Cheatham, FAAO, DIP ABO DISCLOSURE STATEMENT We have no direct financial or proprietary interest in any companies, products or services mentioned in
More informationPulsed mode versus near-continuous mode delivery of diode laser photocoagulation for high-risk retinopathy of prematurity
Pulsed mode versus near-continuous mode delivery of diode laser photocoagulation for high-risk retinopathy of prematurity Evelyn A. Paysse, MD, a,b Mohamed A.W. Hussein, MD, a Aaron M. Miller, MD, a Kathryn
More informationPlease check appropriate box: Right Left. Bilateral Not Applicable
UNIVERSITY MEDICAL CENTER DISCLOSURE AND CONSENT - MEDICAL AND SURGICAL PROCEDURES TO THE PATIENT: You have the right as a patient to be informed about your condition and the recommended surgical, medical
More informationForm 6: Baby Outcomes Outcomes at THIS hospital
Form 6: Baby Outcomes Outcomes at THIS hospital Please complete in black ballpoint pen Hospital name: Form 6: Baby Outcomes Please complete this form when a Baby-OSCAR participant is transferred to another
More informationof prematurity (ROP) treated by peripheral cryopexy
British Journal of Ophthalmology, 1984, 68, 36-41 A clinicopathological case of retinopathy of prematurity (ROP) treated by peripheral cryopexy I. NISSENKORN,' I. KREMER,' I. BEN SIRA,' S. COHEN,' AND
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationVascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure
DOI 10.1186/s40942-016-0055-6 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of
More informationAnti-vascular endothelial growth factor treatment for retinopathy of prematurity
Review Article Page 1 of 7 Anti-vascular endothelial growth factor treatment for retinopathy of prematurity Qiujing Huang, Peiquan Zhao Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai
More informationRETINAL DETACHMENT AT THE POSTERIOR POLE*
Brit. J. Ophthal. (1958) 42, 749. RETINAL DETACHMENT AT THE POSTERIOR POLE* BY CALBERT I. PHILLIPSt Institute of Ophthalmology, University oflondon THE common feature of the cases to be described in this
More informationScreening for retinopathy of prematurity at Cipto Mangunkusumo Hospital, Jakarta, Indonesia a preliminary report
ACTA MEDICA LITUANICA. 2006. VOLUME 13 No. 3. P. 165 170 Lietuvos mokslų akademija, 2006 Screening for retinopathy of prematurity at Cipto Mangunkusumo Hospital, Jakarta, Indonesia... 165 Lietuvos mokslų
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationIntravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity
Major Articles Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity Janice C. Law, MD, Franco M. Recchia, MD, David G. Morrison, MD, Sean P. Donahue, MD, PhD, and Robert L. Estes,
More informationCriteria for the timing of the initial retinal examination to screen for retinopathy of prematurity
VOL. 35 NO. PHILIPPINE JOURNAL OF Ophthalmology JANUARY ORIGINAL ARTICLE JUNE 00 Milagros H. Arroyo, MD, MPH - Dino L. Camonias, MD Andrea Kristina Monzon-Pajarillo, MD Farlah Angela M. Salvosa-Sevilla,
More informationIndex. Note: Page numbers with f and t indicate figures and tables, respectively.
Index Note: Page numbers with f and t indicate figures and tables, respectively. A Action Plan on Eye Health VISION 2020 Latin America, 140 Aggressive posterior retinopathy of prematurity (APROP), 21,
More informationPhase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity PROTOCOL IND # 122552 Version 1.0 January 12, 2015 ROP1Protocol v1.0 1-12-15
More informationDOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος
DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008
More information10. ADVANCED RETINOPATHY OF PREMATURITY
Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System as agreed by the Interterritorial Board. 10. ADVANCED
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationMichael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015
Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue
More informationCLINICAL SCIENCES. Rajeev H. Muni, MD, FRCSC; Radha P. Kohly, MD, FRCSC, PhD; Alexander C. Charonis, MD; Thomas C. Lee, MD
CLINICL SCIENCES Retinoschisis Detected With Handheld Spectral-Domain Optical Coherence Tomography in Neonates With dvanced Retinopathy of Prematurity Rajeev H. Muni, MD, FRCSC; Radha P. Kohly, MD, FRCSC,
More informationClinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital
Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up
More informationEarly retinopathy of prematurity findings identified with fluorescein angiography
Graefes Arch Clin Exp Ophthalmol (2013) 251:2093 2097 DOI 10.1007/s00417-013-2321-8 RETINAL DISORDERS Early retinopathy of prematurity findings identified with fluorescein angiography L. Consuelo Zepeda-Romero
More informationHIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR
HIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR HAEMORRHAGE. Stephen A.M. De Souza MD, FRCSC Matthew J Welch MD, Raza M Shah MD, Alan
More informationCombined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases
Kodama et al. BMC Ophthalmology 2014, 14:36 CASE REPORT Open Access Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in
More informationRetinopathy Of Prematurity (or) Retrolental Fibroplasia )
Medical Information Document On Retinopathy Of Prematurity (or) Retrolental Fibroplasia ) What we see is made in the brain from signals given to it by the eyes. What we see is in fact made in the brain.
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationTiffany L. Kruger, D.O. Children s Hospital of Michigan Wayne State University/Kresge Eye Institute
Pediatric Cases Nt Not To Be Missed Tiffany L. Kruger, D.O. Pediatric Ophthalmology Fellow Children s Hospital of Michigan Wayne State University/Kresge Eye Institute Case Presentation CC: Left eye turns
More informationRetinopathy of Prematurity Current Trends and Advances. Susmito Biswas Consultant Paediatric Ophthalmologist Manchester Royal Eye Hospital
Retinopathy of Prematurity Current Trends and Advances Susmito Biswas Consultant Paediatric Ophthalmologist Manchester Royal Eye Hospital Preventative strategies Neonatal care Oxygen management Optimising
More informationAnti-VEGF for ROP and Pediatric Retinal Diseases. An-Lun Wu, MD,* and Wei-Chi Wu, MD, PhD*
REVIEW ARTICLE Anti-VEGF for ROP and Pediatric Retinal Diseases An-Lun Wu, MD,* and Wei-Chi Wu, MD, PhD* Abstract: Vascular endothelial growth factor (VEGF) is an important mediator of the pathological
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationStructural outcomes of eyes with threshold retinopathy of prematurity treated with laser therapy or cryotherapy
ORIGINAL RESEARCH Structural outcomes of eyes with threshold retinopathy of prematurity treated with laser therapy or cryotherapy Wai-Ho Chan, FCOphthHK, FHKAM (Ophth), Chi-Kin Ho, FCOphthHK, FHKAM (Ophth),
More informationSurgical Results and Visual Outcomes of Vitreous Surgery for Advanced Stages of Retinopathy of Prematurity
Surgical Results and Visual Outcomes of Vitreous Surgery for Advanced Stages of Retinopathy of Prematurity Toshihiro Kono, Kenji Oshima and Yuki Fuchino Department of Ophthalmology, School of Medicine,
More informationFINAL RESULTS OF THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY (ETROP) RANDOMIZED TRIAL
FINAL RESULTS OF THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY (ETROP) RANDOMIZED TRIAL BY William V. Good MD,* on behalf of the Early Treatment for Retinopathy of Prematurity Cooperative Group ABSTRACT
More informationControversies in Pediatric Refractive Development Timothy Hug, OD, FAAO
Controversies in Pediatric Refractive Development Timothy Hug, OD, FAAO Please silence all mobile devices and remove items from chairs so others can sit. Unauthorized recording of this session is prohibited
More informationINTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY Comparison Between Ranibizumab and Bevacizumab SAN-NI CHEN, MD,* IEBIN LIAN, PHD, YA-CHI HWANG, MD,* YI-HSING
More informationAcknowledgements. Outline. Who were von Hippel and Lindau? Eugen von Hippel German Ophthalmologist
Ophthalmic Therapies & Standard of Care Acknowledgements Eric Jonasch, MD & Surena Matin, MD Collaborators Franco DeMonte, MD Marcy Johnson Ian McCutcheon, MD Chaan Ng, MD Nancy Perrier, MD Dawid Schellingerhout,
More informationScreening Examination of Premature Infants for Retinopathy of Prematurity
Screening Examination of Premature Infants for Retinopathy of Prematurity (1) Overview material Release Date 2006 Status Available in Electronic Format Available in Print Format Bibliographic citation
More informationOptical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP
Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features
More informationMarcus Gonzales, OD, FAAO Cedar Springs Eye Clinic
Marcus Gonzales, OD, FAAO Cedar Springs Eye Clinic 25.6 million adults 11.3% of the adult population 10.9 million adults 65 years and older 26.9% of this age population 79 million people are Pre-diabetic!!
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationR etinopathy of prematurity (ROP), a condition confined
F240 ORIGINAL ARTICLE UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome L Haines, A R Fielder, H Baker, A R Wilkinson... See end of article for authors affiliations...
More informationDehiscence of detached internal limiting membrane in eyes with myopic traction maculopathy with spontaneous resolution
Hirota et al. BMC Ophthalmology 2014, 14:39 RESEARCH ARTICLE Open Access Dehiscence of detached internal limiting membrane in eyes with myopic traction maculopathy with spontaneous resolution Kazunari
More informationInsulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come
Insulin-Like Growth Factor-1 and Anti-Vascular Endothelial Growth Factor in Retinopathy of Prematurity: Has the Time Come The Harvard community has made this article openly available. Please share how
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationClinical Policy: Verteporfin (Visudyne) Reference Number: CP.PHAR.187
Clinical Policy: (Visudyne) Reference Number: CP.PHAR.187 Effective Date: 03/16 Last Review Date: 03/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationWhat s New in Pediatric Ophthalmology
What s New in Pediatric Ophthalmology Forrest J Ellis MD Northern Virginia Ophthalmology Associates Falls Church, Fairfax, Alexandria (Milan, Paris, Singapore, London) What s New Myopia treatment Retinopathy
More informationIntravitreal low-dosage bevacizumab for retinopathy of prematurity
Intravitreal low-dosage bevacizumab for retinopathy of prematurity Bj orn C. Harder, Stefan von Baltz, Jost B. Jonas and Frank C. Schlichtenbrede Department of Ophthalmology, Medical Faculty Mannheim,
More informationIs OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema
Is OCT-A Needed As An Investigative Tool During The Management Of Diabetic Macular Edema Ayman M Khattab MD, FRCS Professor of Ophthalmology Cairo University Diabetic Macular Edema (DME) Diabetic macular
More informationThe Diabetic Retinopathy Clinical Research Network. Management of DME in Eyes with PDR
The Diabetic Retinopathy Clinical Research Network Management of DME in Eyes with PDR 1 What Has Been Learned? Diabetic Retinopathy Treatment Protocol F: Results suggest that clinically meaningful differences
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More information